G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer

References

• American Cancer Society. Breast Cancer: Facts and Figures 2013–2014. Atlanta (GA): American Cancer Society, Inc; 2013.
   Google Scholar
• Metzger-Filho O, Sun Z, Viale G, Price KN, Crivellari D, Snyder RD, Gelber RD, Castiglione-Gertsch M, Coates AS, Goldhirsch A, et al. Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol. 2013;3125:3083-90. doi:10.1200/JCO.2012.46.1574
   Web of Science ®Google Scholar
• Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012; 486:346-52. PMID:22522925
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61-70. doi:10.1038/nature11412. PMID:23000897
   PubMed Web of Science ®Google Scholar
• Kemp-Casey A, Roughead ER, Saunders C, Boyle F, Lopez D, Bulsara M, Preen DB. Breast cancer recurrence following active treatment: determining its incidence in the NSW population. Public Health Res Pract. 2016;26:2611607. doi:10.17061/phrp2611607. PMID:26863170
   PubMed Web of Science ®Google Scholar
• Brown S. Improvements in breast cancer recurrence. Post Reprod Health. 2015;214:137-8. doi:10.1177/2053369115613292
   Google Scholar
• Almstedt K, Schmidt M. Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer. Breast Care (Basel). 2015;10:168-72. doi:10.1159/000405017. PMID:26557821
   PubMed Web of Science ®Google Scholar
• Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, González-Angulo AM, Mills GB, Miller WR, Wu, et al. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. Clin Cancer Res. 2011;17:2024-34. doi:10.1158/1078-0432.CCR-10-2567. PMID:21346144
   PubMed Web of Science ®Google Scholar
• Dey N, De P, Leyland-Jones B. PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials. Pharmacol Ther. 2017;S0163-7258:30051-7.
   Google Scholar
• Miller TW, Hennessy BT, Gonzalez-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, Garcia-Echeverria C, Shyr Y, Arteaga CL Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest. 2010;120:2406-13. doi:10.1172/JCI41680. PMID:20530877
   PubMed Web of Science ®Google Scholar
• Cavazzoni A, Bonelli MA, Fumarola C, La Monica S, Airoud K, Bertoni R, Alfieri R., Galetti M, Tramonti S, Galvani E, et al. Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. Cancer Lett. 2012; 323:77-87. doi:10.1016/j.canlet.2012.03.034. PMID:22484466
   PubMed Web of Science ®Google Scholar
• Ciruelos Gil EM. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat Rev. 2014;40:862-71. doi:10.1016/j.ctrv.2014.03.004. PMID:24774538
   PubMed Web of Science ®Google Scholar
• Yang SX, Polley E, Lipkowitz S. New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer. Cancer Treat Rev. 2016;45:87-96. doi:10.1016/j.ctrv.2016.03.004. PMID:26995633
   PubMed Web of Science ®Google Scholar
• Hosford SR, Miller TW. Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmgenomics Pers Med. 2014;7:203-15. PMID:25206307
   PubMedGoogle Scholar
• Heckmann BL, Zhang X, Xie X., Liu J. The G0/G1 Switch Gene 2 (G0S2): Regulating metabolism and beyond. Biochim Biophys Acta. 2013;1831:276-81. doi:10.1016/j.bbalip.2012.09.016. PMID:23032787
   PubMed Web of Science ®Google Scholar
• Yang X, Lu X, Lombès M, Rha GB, Chi YI, Guerin TM, Smart EJ, Liu J. The G(0)/G(1) switch gene 2 regulates adipose lipolysis through association with adipose triglyceride lipase. Cell Metab. 2010;11:194-205. doi:10.1016/j.cmet.2010.02.003. PMID:20197052
   PubMed Web of Science ®Google Scholar
• Ma T, Lopez-Aguiar AG, Li A, Lu Y, Sekula D, Nattie EE, Freemantle S, Dmitrovsky E. Mice lacking G0S2 are lean and cold-tolerant. Cancer Biol Ther. 2014;15:643-50. doi:10.4161/cbt.28251. PMID:24556704
   PubMed Web of Science ®Google Scholar
• Zhang X, Xie X, Heckmann BL, Saarinen AM, Czyzyk TA, Liu J. Targeted disruption of G0/G1 switch gene 2 enhances adipose lipolysis, alters hepatic energy balance, and alleviates high-fat diet-induced liver steatosis. Diabetes. 2014;63:934-46. doi:10.2337/db13-1422. PMID:24194501
   PubMed Web of Science ®Google Scholar
• Kusakabe M, Kutomi T, Watanabe K, Emoto N, Aki N, Kage H, Hamano E, Kitagawa H, Nagase T, Sano A, et al. Identification of G0S2 as a gene frequently methylated in squamous lung cancer by combination of in silico and experimental approaches. Int J Cancer. 2010;126:1895-902. PMID:19816938
   PubMed Web of Science ®Google Scholar
• Chang X, Monitto CL, Demokan S, Kim MS, Chang SS, Zhong X, Califano JA, Sidransky D. Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res. 2010;70:2870-379. doi:10.1158/0008-5472.CAN-09-3427. PMID:20215521
   PubMed Web of Science ®Google Scholar
• Choi H, Lee H, Kim TH, Kim HJ, Lee YJ, Lee SJ, Yu JH, Kim D, Kim KS, Park SW, et al G0/G1 switch gene 2 has a critical role in adipocyte differentiation. Cell Death Diffe.r 2014;21:1071-80. doi:10.1038/cdd.2014.26
   PubMed Web of Science ®Google Scholar
• Yamada T, Park CS, Shen Y, Rabin KR, Lacorazza HD. G0S2 inhibits the proliferation of K562 cells by interacting with nucleolin in the cytosol. Leuk Res 2014;38:210-7. doi:10.1016/j.leukres.2013.10.006. PMID:24183236
   PubMed Web of Science ®Google Scholar
• Yamada T, Park CS, Burns A, Nakada D, Lacorazza HD. The cytosolic protein G0S2 maintains quiescence in hematopoietic stem cells. PLoS One. 2012;7:e38280. doi:10.1371/journal.pone.0038280. PMID:22693613
   PubMed Web of Science ®Google Scholar
• Welch C, Santra MK, El-Assaad W, Zhu X, Huber WE, Keys RA, Teodoro JG, Green MR. Identification of a protein, G0S2, that lacks Bcl-2 homology domains and interacts with and antagonizes Bcl-2. Cancer Re.s 2009;69:6782-89. doi:10.1158/0008-5472.CAN-09-0128
   PubMed Web of Science ®Google Scholar
• Kitareewan S, Blumen S, Sekula D, Bissonnette RP, Lamph WW, Cui Q, Gallagher R, Dmitrovsky E. G0S2 is an all-trans-retinoic acid target gene. Int J Oncol. 2008;33:397-404. PMID:18636162
   PubMed Web of Science ®Google Scholar
• Yim CY, Sekula DJ, Hever-Jardine MP, Liu X, Warzecha JM, Tam J, Freemantle SJ, Dmitrovsky E, Spinella MJ. G0S2 suppresses oncogenic transformation by repressing a MYC-regulated transcriptional program. Cancer Res. 2016;76:1204-13. doi:10.1158/0008-5472.CAN-15-2265. PMID:26837760
   PubMed Web of Science ®Google Scholar
• Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417-25. doi:10.1016/j.cels.2015.12.004. PMID:26771021
   PubMed Web of Science ®Google Scholar
• Lux MP, Fasching PA, Schrauder MG, Hein A, Jud SM, Rauh C, Beckmann MW. The PI3K Pathway: Background and Treatment Approaches. Breast Care (Basel). 2016;11:398-404. doi:10.1159/000453133. PMID:28228706
   PubMed Web of Science ®Google Scholar
• Jewell JL, Russell RC, Guan KL. Amino acid signalling upstream of mTOR. Nat Rev Mol Cell Biol 2013;14:133-9. doi:10.1038/nrm3522. PMID:23361334
   PubMed Web of Science ®Google Scholar
• Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, Sherlock G, Lewicki J, Shedden K, Clarke MF. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med. 2007;356:217-26. doi:10.1056/NEJMoa063994. PMID:17229949
   PubMed Web of Science ®Google Scholar
• Ma L, Nie L, Liu J, Zhang B, Song S, Sun M, Yang J, Yang Y, Fang X, Hu S, et al. An RNA-seq-based gene expression profiling of radiation-induced tumorigenic mammary epithelial cells. Genomics Proteomics Bioinformatics. 2012;10:326-35. doi:10.1016/j.gpb.2012.11.001. PMID:23317700
   PubMedGoogle Scholar
• Aguirre-Gamboa R, Gomez-Rueda H, Martínez-Ledesma E, Martínez-Torteya A, Chacolla-Huaringa R, Rodriguez-Barrientos A, Tamez-Peña JG, Treviño V. SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS One. 2013;8:e74250. doi:10.1371/journal.pone.0074250. PMID:24066126
   PubMed Web of Science ®Google Scholar
• Turner NC, Neven P, Loibl S, Andre F. Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. Lancet. 2016;S0140-6736:32419-32419.
   Google Scholar
• Steelman LS, Martelli AM, Cocco L, Libra M, Nicoletti F, Abrams SL, McCubrey JA. The therapeutic potential of mTOR inhibitors in breast cancer. Br J Clin Pharmacol. 2016;82:1189-212. doi:10.1111/bcp.12958. PMID:27059645
   PubMed Web of Science ®Google Scholar
• Bosco EE, Wang Y, Xu H, Zilfou JT, Knudsen KE, Aronow BJ, Lowe SW, Knudsen ES. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest. 2007;117:218-28. doi:10.1172/JCI28803. PMID:17160137
   PubMed Web of Science ®Google Scholar
• McNeil CM, Sergio CM, Anderson LR, Inman CK, Eggleton SA, Murphy NC, Millar EK, Crea P, Kench JG, Alles MC, et al. c-Myc overexpression and endocrine resistance in breast cancer. J Steroid Biochem Mol Biol. 2006;102:147-55. doi:10.1016/j.jsbmb.2006.09.028. PMID:17052904
   PubMed Web of Science ®Google Scholar
• Shajahan-Haq AN, Cook KL, Schwartz-Roberts JL, Eltayeb AE, Demas DM, Warri AM, Facey CO, Hilakivi-Clarke LA, Clarke R. MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer. Mol Cancer. 2014;13:239. doi:10.1186/1476-4598-13-239. PMID:25339305
   PubMed Web of Science ®Google Scholar
• Al-azawi D, Ilroy MM, Kelly G, Redmond AM, Bane FT, Cocchiglia S, Hill AD, Young LS. Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer. Oncogene. 2008;27:3021-31. doi:10.1038/sj.onc.1210964. PMID:18059336
   PubMed Web of Science ®Google Scholar
• Green AR, Aleskandarany MA, Agarwal D, Elsheikh S, Nolan CC, Diez-Rodriguez M, Macmillan RD, Ball GR, Caldas C, Madhusudan S et al. MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. Br J Cance.r 2016;114:917-28. doi:10.1038/bjc.2016.46
   PubMed Web of Science ®Google Scholar
• Rodrik-Outmezguine VS, Okaniwa M, Yao Z, Novotny CJ, McWhirter C, Banaji A, Won H, Wong W, Berger M, de Stanchina E, et al. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature. 2016;534:272-6. PMID:27279227
   PubMed Web of Science ®Google Scholar
• Seront E, Pinto A, Bouzin C, Bertrand L, Machiels JP, Feron O. PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation. Br J Cancer. 2013;109:1586-92. doi:10.1038/bjc.2013.505. PMID:23989949
   PubMed Web of Science ®Google Scholar
• Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19:575-86. doi:10.1016/j.ccr.2011.04.008. PMID:21575859
   PubMed Web of Science ®Google Scholar
• Dey N, Leyland-Jones B, De P. MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers. Am J Cancer Res. 2014;5:1-19. PMID:25628917
   PubMed Web of Science ®Google Scholar
• Ilic N, Utermark T, Widlund HR, Roberts TM. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci USA. 2011;108:E699−708. doi:10.1073/pnas.1108237108. PMID:21876152
   PubMed Web of Science ®Google Scholar
• Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;365:671-9. doi:10.1016/S0140-6736(05)70933-8. PMID:15721472
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006;98(4):262-72. doi:10.1093/jnci/djj052. PMID:16478745
   PubMed Web of Science ®Google Scholar
• Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 2006;66:10292-301. doi:10.1158/0008-5472.CAN-05-4414. PMID:17079448
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sieuwerts AM, McGreevy M, Casey G, Cufer T, Paradiso A, Harbeck N, Span PN, Hicks DG, Crowe J, et al. The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat. 2009;116:303-9. doi:10.1007/s10549-008-0183-2. PMID:18821012
   PubMed Web of Science ®Google Scholar